Pfizer completed the acquisition of Therachon Holding, a privately-held clinical-stage biotechnology company focused on rare diseases, with assets in development for the treatment of achondroplasia and short bowel syndrome for $340m upfront with an additional $470m. Achondroplasia can result in serious cardiovascular, neurological and metabolic complications for approximately 250k people worldwide. There are currently no approved treatments for achondroplasia. “At Pfizer, our strategy is focused on advancing the most promising science in the world, regardless of whether it is found inside or outside of our labs. By acquiring Therachon, we hope to leverage Pfizer’s leading scientific and development capabilities to more rapidly advance this potentially promising therapy for people with achondroplasia,” Mikael Dolsten, Pfizer Chief Scientific Officer and President, Worldwide Research, Development, and Medical.